This is a cost effectiveness model for evaluating the cost effectiveness of rTMS versus pharmacotherapy for the treatment of patients with major depressive disorder who have failed at least two adequate courses of antidepressant medications. The model is developed in TreeAge pro suite and contains all the information required to generate the results presented in the paper "Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment Resistant Depression", published in Value in Health (2015
Objective: Antidepressant drugs and cognitive-behavioural therapy (CBT) are effective treatment opti...
To determine effectiveness and cost-effectiveness over a one-year time horizon of pharmacological fi...
Cost-effectiveness studies are a useful tool in drug-choice decisions. They are appropriate when alt...
AbstractBackgroundRepetitive transcranial magnetic stimulation (rTMS) therapy is a clinically safe, ...
Background: Repetitive transcranial magnetic stimulation (rTMS) therapy is a clinically safe, noninv...
Repetitive Transcranial Magnetic Stimulation (rTMS) commonly is used for the treatment of Major Depr...
ObjectiveRepetitive Transcranial Magnetic Stimulation (rTMS) commonly is used for the treatment of M...
Introduction: Transcranial magnetic stim-ulation (TMS) is a novel antidepressant therapy shown to be...
Major depressive disorder (MDD) is one of the most common psychiatric disorders, however, current tr...
Si-Tien Wang,1 Ian M Anderson,2 Dominic Mitchell,3 Scott J Johnson,1 Aki Shiozawa4,5 1Medicus Econom...
Background: It is estimated that major depression disorders constitute 8.2 of years lived with disab...
BACKGROUND: Major depressive disorder (MDD) is one of the most common psychiatric disorders, however...
BACKGROUND: Major depressive disorder (MDD) is one of the most common psychiatric disorders, however...
Abstract Background Knowledge regarding the relative cost-effectiveness of different antidepressants...
Abstract Background Decision makers in many jurisdictions use cost-effectiveness estimates as an aid...
Objective: Antidepressant drugs and cognitive-behavioural therapy (CBT) are effective treatment opti...
To determine effectiveness and cost-effectiveness over a one-year time horizon of pharmacological fi...
Cost-effectiveness studies are a useful tool in drug-choice decisions. They are appropriate when alt...
AbstractBackgroundRepetitive transcranial magnetic stimulation (rTMS) therapy is a clinically safe, ...
Background: Repetitive transcranial magnetic stimulation (rTMS) therapy is a clinically safe, noninv...
Repetitive Transcranial Magnetic Stimulation (rTMS) commonly is used for the treatment of Major Depr...
ObjectiveRepetitive Transcranial Magnetic Stimulation (rTMS) commonly is used for the treatment of M...
Introduction: Transcranial magnetic stim-ulation (TMS) is a novel antidepressant therapy shown to be...
Major depressive disorder (MDD) is one of the most common psychiatric disorders, however, current tr...
Si-Tien Wang,1 Ian M Anderson,2 Dominic Mitchell,3 Scott J Johnson,1 Aki Shiozawa4,5 1Medicus Econom...
Background: It is estimated that major depression disorders constitute 8.2 of years lived with disab...
BACKGROUND: Major depressive disorder (MDD) is one of the most common psychiatric disorders, however...
BACKGROUND: Major depressive disorder (MDD) is one of the most common psychiatric disorders, however...
Abstract Background Knowledge regarding the relative cost-effectiveness of different antidepressants...
Abstract Background Decision makers in many jurisdictions use cost-effectiveness estimates as an aid...
Objective: Antidepressant drugs and cognitive-behavioural therapy (CBT) are effective treatment opti...
To determine effectiveness and cost-effectiveness over a one-year time horizon of pharmacological fi...
Cost-effectiveness studies are a useful tool in drug-choice decisions. They are appropriate when alt...